Уважаемые коллеги, доброго времени суток! Представляем вам нидерландское научное издание Journal of Affective Disorders. Журнал имеет первый квартиль, издаётся в Elsevier, его SJR за 2022 г. равен 1,988, импакт-фактор 6,533, печатный ISSN - 0165-0327, электронный - 1573-2517, предметные области - Психиатрия и психическое здоровье, Клиническая психология. Вот так выглядит обложка:
Здесь два редактора - Паола Брамбилла, контактные данные - paolo.brambilla1@unimi.it, paola.brambilla@unimi.it.
и Джейр Соарес - Jair.C.Soares@uth.tmc.edu.
К публикации принимаются статьи, посвященные аффективным расстройствам в самом широком смысле: депрессии, мании, спектру настроения, эмоциям и личности, тревоге и стрессу. Журнал носит междисциплинарный характер и направлен на объединение различных подходов для самой разнообразной читательской аудитории. Будут приниматься статьи высочайшего качества, касающиеся любого аспекта аффективных расстройств, включая нейровизуализацию, когнитивную неврологию, генетику, молекулярную биологию, экспериментальную и клиническую неврологию, фармакологию, нейроиммуноэндокринологию, интервенционные исследования и методы лечения.
Адрес издания - https://www.sciencedirect.com/journal/journal-of-affective-disorders
Пример статьи, название - Efficacy and safety of repetitive transcranial magnetic stimulation combined with antidepressants in children and adolescents with depression: A systematic review and meta-analysis. Заголовок (Abstract)
Background
Repetitive Transcranial magnetic stimulation (rTMS) combined with antidepressants benefited adults with depression while its efficacy and safety in children and adolescents with depression remain controversial.
Methods
We searched PubMed, Embase, the Cochrane Library, Web of Science, CINAHL, LILACS, PsycINFO, CNKI, Wanfang Data Knowledge Service Platform, a Chinese Biology Medical disc database, and relevant clinical registration databases for randomized controlled trials from their inception to October 18, 2022. The efficacy of the treatment was assessed by changes in depression rating scale scores. Safety was assessed by the incidence of adverse events. Heterogeneity was determined using the Cochrane Q statistics and I2 statistics. Publication bias was assessed by Egger's test.
Results
Eighteen studies from 10 datasets (1396 patients, 64.7 % female, age range from 8 to 24 years old). The pooled mean-endpoint scores of the depression scale for rTMS combined with the antidepressant group were significantly lower than those of sham combined with the antidepressant group both in two weeks (MD = -4.68, 95 % CI: [−6.66, −2.69]; I2 = 91 %; P < 0.05) and four weeks (MD = −5.53, 95 % CI: [−9.90, −1.16]; I2 = 98 %; P < 0.05). There were no differences in safety (OR = 0.64, 95 % CI: [0.20, 2.04]; I2 = 64 %; P = 0.45) and acceptability between the two groups (3/70 vs 3/70).
Limitation
Heterogeneity was found in this study due to the limited number of original studies included.
Conclusion
rTMS combined with antidepressants enhanced the efficacy of the antidepressant medication. The safety and acceptability of the two groups were comparable. These findings may help guide future research and clinical practice.
Keywords: Repetitive transcranial magnetic stimulation (rTMS); Antidepressants; Adolescents and children; Efficacy; Safety; Depression